FOIAengine: Requests to SEC Preceded Stock Troubles and a Surprise Resignation For a company that most Americans have never heard of, Medpace Holdings, Inc. (NASD:MEDP) sits remarkably close to the center of the modern drug-development economy. The Cincinnati-based...
FOIAengine: Assessments Include Operational, Clinical and Commercial Threats Freedom of Information Act requests to the Food and Drug Administration during March illustrated three of the primary uncertainties facing U.S. drug manufacturers and their investors: the...
FOIAengine: Journalists Seek EPA Communications on Iran Bombing A small circle of reporters – concentrated overwhelming at one news organization – is using the Freedom of Information Act to run what amounts to a systematic, real-time audit of Environmental Protection...
How FOIA Requests Signaled Problems With a “Bionic Pancreas” At a federal advisory panel meeting in 2018, a biomedical engineer named Ed Damiano stepped to the microphone – not just as a scientist. “I’m also a father,” he told regulators, describing his son’s...
FOIAengine: Advocates on Both Sides Push FDA for Data as a Senate Investigation Begins Even before Sen. Josh Hawley (R-Mo.) walked into a March 11 news conference to kick off an effort to ban the abortion drug mifepristone as unsafe – and days before he opened an...
FOIAengine: How FOIA Requests Pointed to Problems at Boston Scientific Months before Boston Scientific expanded its urgent warning this month about the risk of sudden death from its Accolade pacemakers, something quieter was happening inside the U.S. Food and Drug...
